scholarly journals Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial

2014 ◽  
Vol 165 (4) ◽  
pp. 575-578 ◽  
Author(s):  
Michelle Furtado ◽  
Martin J. S. Dyer ◽  
Rod Johnson ◽  
Margie Berrow ◽  
Simon Rule
Keyword(s):  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
Mantle Cell

A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. TPS223-TPS223 ◽  
Author(s):  
V. A. Morrison ◽  
S. Jung ◽  
J. L. Johnson ◽  
J. Leonard ◽  
B. D. Cheson ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
Mantle Cell

scholarly journals Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

2015 ◽  
Vol 172 (2) ◽  
pp. 208-218 ◽  
Author(s):  
Brian G. Till ◽  
Hongli Li ◽  
Steven H. Bernstein ◽  
Richard I. Fisher ◽  
W. Richard Burack ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Induction Therapy ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
Newly Diagnosed ◽  
Mantle Cell

scholarly journals Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial

Leukemia ◽  
2015 ◽  
Vol 30 (4) ◽  
pp. 984-987 ◽  
Author(s):  
S Ferrero ◽  
◽  
A Pastore ◽  
C W Scholz ◽  
R Forstpointner ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
Mantle Cell

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

2018 ◽  
Vol 18 (9) ◽  
pp. 569-575.e1 ◽  
Author(s):  
Victor Yazbeck ◽  
Danielle Shafer ◽  
Edward B. Perkins ◽  
Domenico Coppola ◽  
Lubomir Sokol ◽  
...  
Keyword(s):  
B Cell ◽  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Mantle Cell ◽  
Large B Cell

scholarly journals A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma

Haematologica ◽  
2012 ◽  
Vol 97 (7) ◽  
pp. 1085-1091 ◽  
Author(s):  
C. Renner ◽  
P. L. Zinzani ◽  
R. Gressin ◽  
D. Klingbiel ◽  
P.-Y. Dietrich ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
Single Agent ◽  
Multicenter Phase ◽  
Mantle Cell

Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003)

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 262-262 ◽  
Author(s):  
Pier Luigi Zinzani ◽  
Thomas E. Witzig ◽  
Julie M. Vose ◽  
Craig B. Reeder ◽  
Rena Buckstein ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Cell Lymphoma ◽  
Single Agent ◽  
Progression Free Survival ◽  
Prior Treatment ◽  
Efficacy And Safety ◽  
Mantle Cell ◽  
Measurable Disease

Abstract Introduction: Mantle-cell lymphoma (MCL) is a type of B-cell non-Hodgkin lymphoma (NHL) that typically responds to initial chemo-immunotherapy, but with a relatively short duration of response (DR) and progression-free survival (PFS) when treated with conventional chemotherapy agents. Although the overall survival (OS) of MCL has improved, most patients are not cured and new agents are needed. A sub-analysis of a recent phase II trial (NHL-002) investigating the efficacy and safety of lenalidomide in patients with relapsed or refractory MCL, demonstrated a promising overall response rate (ORR) of 53% with a median DR of 11.9 months. A confirmatory international phase II trial (NHL-003) of single-agent lenalidomide was initiated for patients with relapsed/refractory aggressive NHL that had received at least one prior treatment and had measurable disease. In this report, we analyze the current results from the MCL patients enrolled in this trial. Methods: Patients with relapsed or refractory MCL and measurable disease ≥2 cm after at least 1 prior treatment regimen were eligible. Patients received 25 mg of lenalidomide orally once daily on days 1–21 of every 28-day cycle. Patients continued therapy until disease progression or toxicity. The 1999 IWLRC methodology was used to assess response and progression. Results: This report focuses on the 39 MCL patients that were enrolled and evaluable for response assessment. Median age was 66 (33–82) years and 29 (74%) patients were male. Median time from diagnosis to lenalidomide treatment was 3.4 (0.4–9) years. Patients had received a median of 3 (1–8) prior treatments, and 23% (9/39) of patients had received prior bortezomib treatment. The ORR with lenalidomide was 41% (16/39), including 13% (5/39) complete response (CR)/unconfirmed CR, and 28% (11/39) partial responses. Ten (26%) patients had stable disease. The most common grade 3 or 4 adverse events were neutropenia (51%) and thrombocytopenia (25%), anemia (13%), fatigue (10%) and febrile neutropenia (10%). Conclusion: These results confirm that lenalidomide oral monotherapy is effective in the treatment of patients with relapsed or refractory MCL, with manageable side effects.

Sign in / Sign up

Export Citation Format

Share Document